DXCM vs ENOV Stock Comparison
ENOV currently leads DXCM in this stock comparison, with AIQ scores of 60 vs 51. The clearest difference is value, while DXCM has the stronger quality profile.
What is the main difference between DXCM and ENOV?
ENOV leads the current stock comparison as Enovis Corporation, with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
DexCom, Inc. vs Enovis Corporation
ENOV leads
ENOV leads by 9 AIQ points, primarily on Value and Momentum, having only recently taken the lead back from DXCM.
Fragile: 3 of 6 evidence groups support ENOV, the lead recently changed hands, and its current signal state is conflicted.
DexCom, Inc.
Enovis Corporation
The Algovestiq AIQ Score currently favors ENOV over DXCM, 60 versus 51 as of Oct 31, 2026. ENOV's advantage is driven primarily by stronger value and momentum, while DXCM holds the stronger quality profile. ENOV also shows the stronger technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor ENOV today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. ENOV lead: Reversed — DXCM led by 1 AIQ points 30 sessions ago; ENOV now leads by 9.
Compare DexCom, Inc. and Enovis Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare DXCM and ENOV against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value28 vs 74ENOV +46
- Quality86 vs 42DXCM +44
- Momentum33 vs 73ENOV +40
- Risk Resilience54 vs 46DXCM +8
3 of 6 evidence groups favor ENOV. ENOV’s edge is concentrated in value and momentum; DXCM keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-10-28, compared against the prior scored session 2026-10-27.
No factor moved materially.
No signal started or stopped since the prior session; its 2 active signals are unchanged.
Largest factor move: Risk Resilience +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 6 active signals are unchanged.
ENOV's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — DXCM and ENOV both carry a full feed there.
The central trade-off
ENOV (Enovis Corporation): the stronger current systematic profile, led by value and momentum.
DXCM (DexCom, Inc.): the counter-case, on quality, risk resilience, fundamentals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ENOVENOV on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ENOVENOV on combined revenue and EPS growth.
Value
ENOVENOV on the peer-relative Value factor, by 46 points.
Momentum
ENOVENOV on the Momentum factor, by 40 points.
Lower downside
DXCMDXCM on Risk Resilience, by 8 points.
Analyst upside
ENOVENOV on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | DXCM | ENOV | Note |
|---|---|---|---|
| Implied upside to target | +12.7% | +82.8% | ENOV has more room |
| Target dispersion | +55% | +65.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 13 | 6 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor ENOV. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ENOV | 51 vs 60 |
| Fundamentals | DXCMon balance | revenue growth 9.8% vs -1.1%; EPS growth 25% vs 86.7%; TTM ROE 36.2% vs -68.2%; gross margin 62.5% vs 57.4%; operating margin 22.9% vs 4.1% — DXCM takes 4 of 5 decided legs, not all of them |
| Valuation | ENOV | Value 28 vs 74 |
| Technicals | DXCM | Price vs 50-day -4.5% vs -1.5%; vs 200-day 5.6% vs -5.2% |
| Risk Resilience | DXCM | Risk Resilience 54 vs 46 |
| Analyst expectations | ENOV | Target upside 12.7% vs 82.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of DXCM and ENOV and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 9 points.
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ENOV.
How the comparison changed
120 daily snapshots · Jun 29 – Oct 28ENOV lead: Reversed — DXCM led by 1 AIQ points 30 sessions ago; ENOV now leads by 9.
- Today
- ENOV +9
- 51 vs 60
- 7 sessions ago
- ENOV +9
- 50 vs 59
- 30 sessions ago
- DXCM +1
- 52 vs 51
- 90 sessions ago
- DXCM +8
- 60 vs 52
The lead changed hands 3 times in this window, most recently on Oct 15 when DXCM moved ahead of ENOV.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 1 bearish, conflicted
Only DXCM
- Golden Cross Active — bullish, trend, long horizon (15.75%)
- MACD Bearish Crossover — bearish, momentum, short horizon
2 bullish / 2 bearish / 2 neutral, conflicted
Only ENOV
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Death Cross Active — bearish, trend, long horizon (14.35%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.24%)
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Overbought — bearish, momentum, short horizon
- MACD Bullish Crossover — bullish, momentum, short horizon
ENOV leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +2.95%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -12.71%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1DXCM closes the Value gap — currently 46 points behind, the largest single contributor to ENOV's edge.
- 2DXCM's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it.
- 3ENOV's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
DXCM leads on balance| Metric | DXCM | ENOV |
|---|---|---|
| Revenue growth (YoY) | 9.8% | -1.1% |
| EPS growth (YoY) | 25% | 86.7% |
| Gross margin | 62.5% | 57.4% |
| Operating margin | 22.9% | 4.1% |
| Return on equity (TTM) | 36.2% | -68.2% |
| Debt to equity | 0.53 | 0.93 |
Performance
DXCM leads 4 of 6 windows| Metric | DXCM | ENOV |
|---|---|---|
| 1 week (5 sessions) | -2% | 5.3% |
| 1 month (20 sessions) | -8.9% | 19.9% |
| 3 months (63 sessions) | 5.5% | -25.2% |
| 6 months (126 sessions) | 36.6% | -2.6% |
| Year to date | 18.5% | -17.8% |
| 1 year (252 sessions) | 11.8% | -33.3% |
Technicals
DXCM has the stronger structure| Metric | DXCM | ENOV |
|---|---|---|
| RSI (14) | 35 | 81.4 |
| ADX (14) | 19 | 27.2 |
| Price vs 50-day | -4.5% | -1.5% |
| Price vs 200-day | 5.6% | -5.2% |
| Volatility (1M, annualized) | 37.2% | 41.4% |
Risk
DXCM is the more resilient| Metric | DXCM | ENOV |
|---|---|---|
| Beta | 0.63 | 1.38 |
| Sharpe ratio | 0.42 | -0.38 |
| Sortino ratio | 0.6 | -0.57 |
| Max drawdown | -22.6% | -47% |
| Current drawdown | -14.9% | -33.3% |
| Annualized volatility | 40.3% | 63.5% |
| Value at risk (95%) | -3.7% | -6.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, DXCM or ENOV?
On the Algovestiq AIQ Score, ENOV is the stronger of the two as of Oct 31, 2026, scoring 60 against DXCM's 51. The edge comes from value and momentum. DXCM is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is DXCM or ENOV the better buy right now?
ENOV carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor ENOV over DXCM?
The composite weights Quality, Value, Momentum and Risk Resilience. ENOV leads Value by 46 points; DXCM leads Quality by 44 points; ENOV leads Momentum by 40 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, DXCM or ENOV?
Analyst price targets imply +12.7% upside for DXCM and +82.8% for ENOV, so the Street currently favors ENOV. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, DXCM or ENOV?
ENOV is the better-valued of the two on the peer-relative Value factor. ENOV on the peer-relative Value factor, by 46 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, DXCM or ENOV?
ENOV on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, DXCM or ENOV?
ENOV on the Momentum factor, by 40 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, DXCM or ENOV?
DXCM is the more resilient of the two, so the other name carries the higher downside risk. DXCM on Risk Resilience, by 8 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is DXCM more profitable than ENOV?
DXCM leads on the comparable margin measures — gross margin 62.5% vs 57.4%; operating margin 22.9% vs 4.1%; ttm roe 36.2% vs -68.2%.
Is ENOV's lead over DXCM getting stronger or weaker?
ENOV lead: Reversed — DXCM led by 1 AIQ points 30 sessions ago; ENOV now leads by 9. This is measured from 120 daily comparison snapshots between 2026-06-29 and 2026-10-28. The lead has changed hands 3 times in that window, most recently on 2026-10-15, when DXCM moved ahead of ENOV.
What would change the DXCM vs ENOV verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: DXCM closes the Value gap — currently 46 points behind, the largest single contributor to ENOV's edge; DXCM's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it; ENOV's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about DXCM and ENOV?
DXCM: 1 bullish / 1 bearish, conflicted. ENOV: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on DXCM is Golden Cross Active (bullish, long horizon). On ENOV it is Death Cross Active (bearish, long horizon).
Compare DXCM and ENOV with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.